Title
Exosomes in semen: Opportunities as a new tool in prostate cancer diagnosis
Date Issued
01 October 2017
Access level
open access
Resource Type
review
Author(s)
Pucci M.
Taverna S.
Reclusa P.
Durendez E.
Lewintre E.J.
Malarani M.
Zito G.
Rolfo C.
Publisher(s)
AME Publishing Company
Abstract
Prostate cancer (PCa) is the most common cancer in men. Nowadays, it is diagnosed through the test of serum prostate-specific antigen (PSA) and rectal examination; however, there is still debate about the PSA-based diagnosis. Seminal fluid (SF), contains a high concentration of subcellular lipid-bound microparticles, traditionally termed "prostasomes", that are extracellular vesicles (EVs) released into the extracellular space by prostate gland's epithelial cells. These vesicles, first described in 1982 promote motility of sperm cells, regulation of sperm cell capacitation, acrosome reaction and immune suppression within the female reproductive tract. It was demonstrated that prostasomes could contain PCa specific molecular fingerprints that can represent the status of their parental cells. Until now the analysis of isolated prostasomes released by PCa cells has proved several advantages compared to the analysis of parental cells. Moreover, the molecular composition of prostasomes could reflect their capacity to influence PCa growth and metastasis. In this review, we discuss the role of prostasomes in PCa, focusing in the possibility of exosomes to represent a non-invasive test for PCa diagnosis and as a possible agent for enhance the sexual transmission diseases (STD) through immunomodulation.
Start page
S1331
End page
S1338
Volume
6
Language
English
OCDE Knowledge area
OncologÃa
UrologÃa, NefrologÃa
Subjects
Scopus EID
2-s2.0-85032582103
Source
Translational Cancer Research
ISSN of the container
2218676X
Sponsor(s)
Antwerp University, Edegem, Belgium; 2Biopathology and Biomedical Methodology, Biology and Genetic section, University of Palermo, Palermo, Italy; 3Institute of Biomedicine and Molecular Immunology (IBIM), National Research Council, Palermo, Italy; 4Unidad de Investigación Básica y Traslacional, Oncosalud-AUNA, Lima, Peru; 5Department of Biotechnology, Universitat Politècnica de València, Molecular Oncology Laboratory, General University Hospital Research Foundation, Valencia, Spain Contributions: (I) Conception and design: M Pucci, S Taverna, C Rolfo; (II) Administrative support: M Pucci, S Taverna, P Reclusa, C Rolfo; (III) Provision of study materials or patients: M Pucci, S Taverna, E Durendez, EJ Lewintre, M Malarani; (IV) Collection and assembly of data: M Pucci, S Taverna, P Reclusa; (V) Data analysis and interpretation: M Pucci, S Taverna, P Reclusa, G Zito; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors. *These authors contributed equally to this work. Correspondence to: Dr. Christian Rolfo. Head of Phase I-Early Clinical Trials Unit, Oncology Department, Antwerp University Hospital, Wilrijkstraat 10, 2650, Edegem, Belgium. Email: christian.rolfo@uza.be.
Sources of information:
Directorio de Producción CientÃfica
Scopus